Skip to main content
TipRanks
Go Ultimate75% OFF

Compare GlaxoSmithKline (GS71) vs. Competitors

6 Followers

Comparison Results

Comparison results
NamePriceMarket CapP/E RatioYearly GainAnalyst ConsensusAnalyst Price TargetCompareTop Analysts' Price TargetSmart ScoreFollow
DE:GS71GlaxoSmithKlineEUR 23.09EUR 92.73B17.8613.41%HoldUnlock the DE:GS71 analyst price target with TipRanks PremiumDE:GS71Unlock the DE:GS71 top-analyst price target with TipRanks Premium
GB:AZNAstraZenecaGBX 14,034.00GBX 217.66B25.993.71%Strong BuyUnlock the GB:AZN analyst price target with TipRanks PremiumDE:GS71 vs GB:AZNUnlock the GB:AZN top-analyst price target with TipRanks Premium
GB:HIKHikma PharmaceuticalsGBX 1,677.00GBX 3.47B12.356.34%Strong BuyUnlock the GB:HIK analyst price target with TipRanks PremiumDE:GS71 vs GB:HIKUnlock the GB:HIK top-analyst price target with TipRanks Premium
GB:SNSmith & NephewGBX 1,176.00GBX 9.83B20.40-5.81%HoldUnlock the GB:SN analyst price target with TipRanks PremiumDE:GS71 vs GB:SNUnlock the GB:SN top-analyst price target with TipRanks Premium
GB:BXPBeximco Pharmaceuticals Limited Sponsored GDR RegSGBX 60.00GBX 67.05B4.6648.15%―Unlock the GB:BXP analyst price target with TipRanks PremiumDE:GS71 vs GB:BXPUnlock the GB:BXP top-analyst price target with TipRanks Premium
GB:HLNHaleon PLCGBX 346.70GBX 30.40B19.11-6.02%Moderate BuyUnlock the GB:HLN analyst price target with TipRanks PremiumDE:GS71 vs GB:HLNUnlock the GB:HLN top-analyst price target with TipRanks Premium

Performance Comparison

-40%-20%0%20%40%60%80%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Performance comparison by fund
TickerCompany NamePriceChange% Change
DE:GS71GlaxoSmithKline23.092.5512.41%
GB:AZNAstraZeneca14034.00670.345.02%
GB:HIKHikma Pharmaceuticals1677.00170.2811.30%
GB:SNSmith & Nephew1176.00-36.34-3.00%
GB:BXPBeximco Pharmaceuticals Limited Sponsored GDR RegS60.0021.3055.06%
GB:HLNHaleon PLC346.70-15.46-4.27%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts